Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal
-
Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting
-
Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation
-
Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune Biomarker Study
-
Aclarion Comments on Echo Lake Capital’s Letter and Unsolicited Proposal
-
Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment
-
Aclarion Announces Inducement Grant to New Commercial Director, Western U.S.
-
Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine
-
Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption
-
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan